Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASKA Pharmaceutical Holdings Co (TSE:4886) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ASKA Pharmaceutical Holdings Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円73,889 Mil.
ASKA Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,356 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASKA Pharmaceutical Holdings Co EV-to-EBIT Related Terms
ASKA Pharmaceutical Holdings Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASKA Pharmaceutical Holdings Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ASKA Pharmaceutical Holdings Co's EV-to-EBIT falls into.
ASKA Pharmaceutical Holdings Co's current Enterprise Value is 円72,080 Mil.
ASKA Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,356 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASKA Pharmaceutical Holdings Co (TSE:4886) has a EV-to-EBIT of 11.34 as of Aug. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. This is 78% above median its historical median of 6.38. Over the past decade, ASKA Pharmaceutical Holdings Co's EV-to-EBIT has ranged from 2.03 to 14.69. According to the industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #239 out of 691 companies in the Drug Manufacturers industry, placing it in the top 34.6%.
Is ASKA Pharmaceutical Holdings Co's EV-to-EBIT too high?
ASKA Pharmaceutical Holdings Co's current EV-to-EBIT of 11.34 is 78% above median its 10-year median of 6.38. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 14.69. The Drug Manufacturers industry median EV-to-EBIT is 15.71. ASKA Pharmaceutical Holdings Co's value of 11.34 is 27.8% below this industry median. Based on the distribution chart, ASKA Pharmaceutical Holdings Co ranks #239 out of 691 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #239 out of 691 companies for EV-to-EBIT. This puts ASKA Pharmaceutical Holdings Co in the upper half of its industry. The industry median EV-to-EBIT is 15.71. ASKA Pharmaceutical Holdings Co's value of 11.34 is 27.8% below this benchmark. Historically, ASKA Pharmaceutical Holdings Co's own EV-to-EBIT has ranged from 2.03 to 14.69 over the past decade. While the company's 10-year median is 6.38 vs. the industry median of 15.71, ASKA Pharmaceutical Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.71, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ASKA Pharmaceutical Holdings Co's current EV-to-EBIT of 11.34 is 27.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASKA Pharmaceutical Holdings Co's current EV-to-EBIT is 11.34, which is 78% above median its own 10-year median of 6.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,409.32, compared to a current price of 円2,138.00 — trading 11.3% below its estimated fair value. The current EV-to-EBIT is 11.34, which is 78% above median its 10-year median of 6.38 and 27.8% below the Drug Manufacturers industry median of 15.71. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 58/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current EV-to-EBIT is 11.34 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of 円2,138.00 is trading 11.3% below its estimated GF Value™ of 円2,409.32.
GuruFocus considers ASKA Pharmaceutical Holdings Co to be Modestly Undervalued.
Key valuation signals for TSE:4886:
EV-to-EBIT: 11.34 (78% above median its 10-year median of 6.38)
GF Value™: 円2,409.32 vs. price of 円2,138.00 (11.3% below fair value)
Industry Position: 27.8% below the Drug Manufacturers median (#239 of 691)
No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
58GF Score
Get the complete analysis for TSE:4886
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4886 has been successfully added to your 
